Kymera Therapeutics: Baker Bros acquire $28.8m in shares

Published 01/07/2025, 01:20
Kymera Therapeutics: Baker Bros acquire $28.8m in shares

Baker Bros. Advisors and related entities reported purchasing shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) on June 30, 2025. The biotechnology company, currently valued at $2.89 billion, has shown strong momentum with a 41% return over the past year. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $53 to $79. The transactions involved the acquisition of 655,500 shares of common stock at a price of $44.00, totaling $28,842,000.

Specifically, 667, L.P. acquired 55,191 shares, while Baker Brothers Life Sciences, L.P. purchased 600,309 shares.

In addition to the common stock, the entities also acquired prefunded warrants, exercisable into Kymera Therapeutics common stock. 667, L.P. acquired 55,191 prefunded warrants and Baker Brothers Life Sciences, L.P. acquired 600,309 prefunded warrants at a price of $43.9999 per warrant.

In other recent news, Kymera Therapeutics has announced a $250 million public stock offering, which includes common stock and pre-funded warrants. The company plans to use the proceeds to advance its degrader programs and for general corporate purposes. This capital raise is significant as it supports the development of Kymera’s pipeline of preclinical and clinical programs. Meanwhile, BofA Securities has raised its price target for Kymera to $54, citing pipeline updates, while H.C. Wainwright increased its target to $60, highlighting the potential of the STAT6 program as a key driver. Brookline Capital Markets, however, lowered its price target to $70 due to changes in revenue timing from collaborations with Sanofi (NASDAQ:SNY). Kymera’s partnership with Gilead Sciences (NASDAQ:GILD) to develop a novel CDK2 degrader also marks a notable business development. Despite the discontinuation of KT-474, Kymera and Sanofi remain committed to advancing KT-485, with clinical trials expected in 2026. These developments underscore Kymera’s ongoing efforts to establish collaborations and optimize its degrader candidates.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.